论文部分内容阅读
自1993年6月～1996年2月应用抗胸腺细胞球蛋白（ATG）预防或治疗各种排斥反应86例，结果7例超急性排斥反应者仍有4例再次发生超急性排斥反应，43例术中及术后加用ATG者仅有5例发生急性排斥反应，14例难治性急性排斥反应者有13例得以逆转，17例肾小管坏死者有16例安全度过急性肾小管坏死期，5例慢性排斥反应者肾功能明显好转。认为ATG能有效地预防急性排斥反应，可使绝大多数耐激素难治性急性排斥反应逆转，而且是急性肾小管坏死过渡期最理想的免疫抑制剂，但不能预防超急性排斥反应及慢性排斥反应。所有患者对ATG耐受良好，少数患者可出现一过性白细胞和血小板减少，短期内适量使用ATG不增加患者的感染机会。
From June 1993 to February 1996 application of anti-thymocyte globulin (ATG) prevention or treatment of 86 cases of various rejection, the results of 7 cases of hyperacute rejection still 4 cases of re-acute hyperacute rejection, 43 cases There were only 5 cases of intraoperative and postoperative ATG with acute rejection, 13 cases of refractory acute rejection were reversed, and 17 cases of renal tubular necrosis had 16 cases of acute phase of acute tubular necrosis , 5 cases of chronic rejection significantly improved renal function. ATG can effectively prevent acute rejection, reversing the vast majority of refractory and refractory acute rejection, and is the most ideal immunosuppressive agent in acute tubular necrosis, but can not prevent hyperacute rejection and chronic rejection reaction. All patients were well tolerated with ATG, transient leukocytosis and thrombocytopenia were present in a small number of patients, and moderate use of ATG in the short term did not increase the chance of infection.